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The mouse ear G 2 m itosis assay was modified for the screeni ng of potential antimitotic 
agents. An inhibit.ory adrenergic innuence, which maintains mitotic rate at a normally low 
level, was removed by pretreatment of mice with reserpine. This depletes endogenous 
catechola mines, produces a state of en ha nced mitotic activity. and makes the epidermal cells 
particularly sensitive to mitotic inhibition by agents which elevate t he levels of cyclic AMP. 
Isoproterenol nC" - 1 x 10- ' MJ, prost.aglandins, dibutyryl cyclic AMP [lC" - 2 x 10- ' 
MJ, papaverine, t heophylline and 5' AMP were inhibitory in the assay. whereas dibutyryl 
cyclic GMP and the cholinergic stimulator carbamylcholine either stimulated or had no 
effect on mitosis. Epidermal growth factor was employed as an alte rnate means of 
stimulating cell divis ion. Skin from newborn mice or rats pretreated with this substance had 
increased epiderm al mitotic activity which was inhibited by cyclic AMP elevators . 
In many biologic systems. cyclic AMP and 
agents which elevate cyclic AMP inhibit prolifera-
tion andlor promote differentiation (see [Ill. Using 
the Bullough assay 12.3 J, Voorhees and co- workers 
14-8J and Marks and Rebien 19J have demon-
strated that the G, stage of the epidermal cell cycle 
is a locus for the antimitotic action of cyclic AMP . 
Since there is evidence for decreased cycle AMP in 
the involved epidermis of psoriatic patients IlOJ.an 
in vitro epiderm al miwsis assay may bave utility 
in identifying potential anLipsoriasis agents which 
act via a mechanism involving cyclic AMP eleva-
tion. The present investigations were undertaken 
to characterize the G2 assay pharmacologicalJy 
with respect to sensitivity t.o cyc lic nucleotide 
effectors and to modify the assay appropriately as 
a screening procedure. 
MATERIALS Al'D METHODS 
Male C3H mice, 70 to 90 days old. were housed 5 per 
cage in a room artificially lighted between 6 am and 8 pm 
and were allowed food and water ad libitum. At least I 
week was allowed to pass after shipment prior to their 
use. 1n experiments where reserpine was em ployed, mice 
we re injected 24 hr prior to sacrifice wi1 h 5 mg per kg 
body weight ip unless otherwise sta ted . 
Assay procedu res employed were modifications of the 
techniques of Bullough and co~workers 12.3/ and of Marrs 
and Voorhees /5/. Mice we re sacrificed by ce rvical 
di slocat ion, both ears were immediat.ely cut off at the 
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Ab breviations: 
I C~o: concent ration producing SOil inh ibition of 
mitosis 
EGF: ep idermal growth factor 
ip: intraperitoneally 
base. and one or I wO 2.5 x 5 m m ea r plugs were obtained 
parallel with the cut edge from each ear wit.h a spec ially 
designed tissue punch , Each plug was placed in a 
separate lO·ml vial comaining 4 ml of Bullough's solution 
\2\ with or wi1hout drugs . In experiment.s where drugs 
were tested. one plug from each mouse served as a conl rol 
and each of the other three were used with different drugs 
or different concent rations of the same drug. Vials were 
cllpped wit.h rubber stoppers. placed in a metaboliC' 
shaker at :n aC and gassed for 10 min with I()()% oxygen 
(Ultra H igh Purity. Matheson) by means of needles 
attached by polyethylene tubing to a manifold . After 1 
hr, 16.5 I1g of colchicin e or demecalcine was added with 8 
sy ringe to each vial in order to arrest mitoses in the 
metaphase stage of cell division. Incubation was then 
continued for an additional <\ hr . 
At the completion of this period. ear plugs were fixed in 
Bouin's solution. dehydrated. and embedded in paraffin. 
Serial seclions were cuI at 7 II thickness and stained with 
hematoxylin and eosin. One slide containing [; se rial 
sections was prepared from each ear plug, and mitolic 
cells were counted in e8ch of the two 5·mm epiderm a l 
surfaces of alternate sections (1st. 3rd. and 5t h \. Avera~e~ 
we re made of I he counts on the three section!' per slide 
and expressed as mitoses per cm surface length . 
Drugs were prepared on the day of experiment in 
double-distilled water, ethanol (prostaglandins). or ().9 ~ 
saline containing .05 g. sodium metabisulfite (iso-
protereno!) . Appropriate vehicle controls were run . A 
volume of .040 ml was added 10 4.0 ml of incubation 
medium . EGF' was isolated from the submaxilla ry glands 
of male Swiss Webster mice according to the method of 
Cohen [II J. The material was purified through the 
Sephadex G-75 column and was stored at _ 20°C until 
use. Colchicine was obtained from Nutril ional Biochemi-
cals; demecolcine. reserpine. and phentolamine from 
Ci ba Pharmaceuticals: ca rbamyl choline and {- ) - iso~ 
prot.erenol-t + l-bitar t.rate from Sigma Chemicals: papav-
erine Hel from Merck: propranolol from Ayerst Labora -
tori es; theophyll ine. adenos ine-5'-monophosphate (5 ' 
AMP) and adellosine-3 ' :5'-cycl ic monophosphate (cyclic 
AMP) from Schwarz Mann: N ~-monobut.yryJ-adeno­
sin e-3 ' :5 ' .cyclic monophosphste (monobutyryl cyclic 
:U3 
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AMP). N '-2 ' - O-dibutyryl-adenosin~-3': 5 ' -cycli c mono-
phosphate (dibutyryl cycLic AMP), 8-bromo-guanosine 
3':5'-cyc1 ic monophosphate (8-bromo-cyc1ic GMP) and 
N 2. 2' -O-dibutyryl - gu8nosine-~' :5' ~cycli(' monophospha te 
(dibutyryl cyclic GMP) from Boehringer Mannheim : and 
prostaglandins E 1 • E " and F ~o from Ono Pharmaceuti-
ca ls. 
RESULTS 
In itial investigations revealed a low control mi-
totic act ivity of 3. 1 ± 0.5 per em of mouse ear 
epidermis. consistent with previously reported val-
ues [5]. Coupled with variability within the four 
plugs from a single mouse. this ci rcumstance 
would require the use of many plugs t.o clearly 
estab lish an inhibitory effect on mitosis in spite of 
easily detectable drug-induced elevations of cyclic 
AMP . For example, isoproterenol. 10- 6 M, was 
found to cause 8 doubling of whole mouse ear cyclic 
AMP (Birnbaum, unpublished observations). Bul -
lough and Laurence [2) have reported the sensitiv-
ity of mit.osis to epinephrine released during stress 
and the relationship of stress to the diurn al mitotic 
cycle of the epidermis . When only animals that 
were asleep at the lime of sacrifice were emp loyed , 
individual counts of 5 or more per cm were 
frequentJy observed. but since avera/Ze count.s were 
only 4.0 ± 0.5 per em. this approach was not 
feasibl e. 
It was considered that normal skin or ci rculat ing 
catecholamines present at the t ime of sacrifice. Or 
elevation of catecholamtne Levels during sacrifice . 
perhaps by release from the adren a l medulla. 
might be exerting an inhibitory influence on mit.o-
s is . Pharmacologic depletion of a mouse's catechol-
amine stores prior to sacrifice might be expected to 
minimize this influen ce. Pretreatment of mi ce with 
reserpine 1121 resuhed in a reproducible. dose- re-
lated elevat ion of basal mitotic count in the in vitro 
ear assay. The data are presented in Table 1. The 
effect was maximum with 2.5 to 5.0 mg per kg ip at 
24 hr and decreased in magllit.ude over the next 24 
hr. Pret reatment with 2.5 mg per kg at both 48 and 
TABLf: 1. Effect of reserpine pretreatment on mouse ear 
epidermal mitosis" 
Pretrealment 
~one 
Reserp ine (24 hr 
pr ior) 
Reserpine (48 hr 
prior) 
Dose 
(mglkp ip) 
1.:l5 
2.,5 
5.0 
1.25 
2.5 
5.0 
M itotic cellslem 
epidermi!i" 
3.5 ± 0.5 
6.~ ± 0.8 
23.6 ± 2.0 
2:3.2 ..r. 3 .1 
2.5 :t: 0.4 
3.2 ± 0.2 
9.5 ± 3 .1 
" M ice were pretreated with reserpine 24 or 48 hr prior 
to sacrifice for experiments. Ear plugs we re incubated fo r 
5 hr in Bullough ·s solution. the last 4 hr in tbe presence of 
colchicine and the number of mitotic ce lls determ ined as 
described under Materials and M ethods. 
/> Mean ± standard error. 
Vol . 66, No . 5 
24 hr prior to sacrifice did not appear to further 
increase mitoses while at 8 hr after t reatment with 
5 mg per kg, mitoses were lower than in controls . In 
subsequent experiments, 24-hr pretreatment with 
reserpine , 5 mg per kg ip, was performed routinely. 
The dose -related, antimitotic effects of iso-
proterenol and several prostaglandins are pre· 
sented in Table II. With isoproterenol, approxi . 
mately 50% in hibition was observed at 10- 11 M . The 
inhibitory effects of isoproterenol, 10- 7 M , were 
completely blocked by propranolol \0- ' M, but 
were unaffected by phen tolamine, 10-' . PGE ,. 
PGE" and PGF,. all inhibited mitosis at adequate 
concentrations. 
Eleva tion of intracellular cyclic AMP by direct 
addition of analogs of this nucleotide to ear plug 
incubations in lieu of addition of adenylaLe cyc lase 
st.imula tors produced similar anti mitotic effects 
(Fig. 1). Dibutyryl cycl ic AMP ca used a dose-
dependent inhibition of m itosis wi th an leu of 
approximately' 2 x 10- ~. At over twice this coneen-
TAB1.E II. Effect of isoproterenol and prostaglandin ... on 
mouse ear epidermal mitosis" 
ComJXlu nd 
( - ) Isoproterenol 
(wilh phento-
\amine. 10- ~ M} 
(with propra -
nolol. 10 !> M) 
PC£, 
PCP, .. 
('oncen· 
tra li un 
(NI ) 
10 .. ~ 1 5 
10- 11 4, 
10- A 85 
10 8, 
10 , 84 
10- 1 
10- " 96 
10 • :16 
10 70 
10 • -4 2 
111 • 52 
10 , 65 
lU 17 
lI\ • 28 
10 ' ;'8 
10 - " 6:3 
10 79 
'if Inh ibi t ion 
uf mit(lsis~ 
" 
181p ~ A51 
" 
14 II' 0 .061 
" 
4 Ip < .0011 
± 3 1p < .0(1) 
" 
61p .006) 
± 20 Ip 0 .98) 
" 
1 (p < .0011 
~ 1.') ( p .081 
, .0 Ip 0 .0051 
± 1.0 (p - .04 ) 
, 1:11 1' - .01 1 
± 81 1' 0 .0011 
± 6( 1' - .09) 
± 141 p . 13 ) 
± 18 (p .(8) 
± 91p .02) 
± lip 0 .006) 
" Mice were pretreated with rese rpine. 5 mg per kg 
hody weight in tra peritoneally. :N hr prior to sacrifice for 
ex periments. Ea r plugs were incubated for 5 hr in the 
presence of Bullough 's solution (containing d rugs), the 
last 4 hr in the presence of demecolcine. Mitotic cells 
were deter mi ned as described under Ma terials and 
M ethod,<;. The numhers of mitoses in isoproterenol-
treated Or PC-treated ea r plugs were compared with 
those in control plugs. Comparisons of means were made 
on the basis of Studen t's I-test and corresponding p 
values a re given in pllTentheses. 
b Mean ± standard error. 
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FIG. 1. Effect of dihutyryl cyclic AMP and dibutyryl 
cyclic GMP on mouse ear epidermal mitusis . Mic.e were 
pretreated with reserpine. [) m~ per k~ body wei~ht 
int.raperitoneaUy. 24 hr prior \0 sacrifice for experiments. 
Ear plugs were incubated for,) hr in Bullough's solution 
\wnlainin~ dibutyryl cyclic AMP or dibutyryl cyclic 
GMP). the last -4 hr in the presence of demecolcine. 
Mit otic cells we re determined as described under Ma teri. 
als and Mdh(Jd~. The numbers of mitoses in drug-treated 
ear plugs were compared with those in control plugs. 
Compari~ms (11' means were made on the oasis of Stu. 
dent's t -test with significance assil'med to corresponding 
p values of .05 ur les~ iindicilted by asleri,.,kL Venical 
bars are standard errors of means. 
tration , cyclic AMP itself was without effect and 
monobutyryl cyclic AMP had interrnediale act.iv-
ity (Tab. If}) . Apparently inhibition was relatively 
selective for the more soluble butyryl fo rms. but 
was not due to the butyryl moiety itself. since 
sodium but~r rate was withoUi effect. Two phospho· 
diesterase inhibitors. papa\'erine a nd theophylline. 
also produced significant inhibition of mitosis at 
10- · M . In ('ontrast to t.hese effects were those of 
dibut,l'r,'1 cyclic GMP (Fig. 1) and carbamyl cho-
line (Tab. In). a cholinergic stimulator. which On 
the avera~e produced either no change or an 
increase in the number of mitotic cells. 
In an effort to 51 imulate epidermal mitosis b.v 
means other than reserpine pretreat ment. t.he 
effects of epidermal growth factor (EG FI. both in 
\'j"o and in vitro were determined in mice (C3H ) 
and rats (Sprague-Dawl e~· ). Pretreatment of adult 
mice (reserpine or non-reserpine pretreated) with 
80 J..ig EGF' subcuta neously 24 hr prior to experi. 
ments did not significant ly alter ear epidermal 
mitoses . Incubation of ear plugs with EGF in \'it ro 
produced on ly inhibit ion of mitosis at concentra-
ti ons from 5.0 J.l. g per ml down to 0.05 J..i ~ per mi. 
Rat s and mice treated daily from birth with 
varying amounts of ECF (subcutaneously) showed 
a dose-related increase in mitoses in the unin -
cubated epidermis of ear. back, and tail relative to 
that of untreated lilt.rmates (Tab . IV ). Rapidly 
growing epidermis is apparently more sensitive to 
the mitogenic action of EGF than is adult epider-
mis_ The time course for EGF-induced mitosis is 
shown in Figure 2. In newborn rats t reated daily 
from birth with EGF. dose-related increases in ear 
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epidermal cell mitosis (up to 60'll) were observed 
as early as day 4, at which time scaling was 
appa rent grossly. By days 7 and 8. when t.ooth 
eruption and eye opening had occu rred in EGF-
treated rats (but not in controls), the increase in 
mitosis was JOO to 2001ff over controls. A decreasing 
effect. in terms of number of mitotic cells, was 
observed with time. and cessation of EGF lreat ~ 
ment was reflected in a return toward control 
mitotic number. In cubation of ear plu~s from 
EGF-treated newborn rats with cyclic AMP elevat -
ing agents reflected antimitotic activity compara-
ble to that observed on ears from non-EGF treated 
littermates (Tab. V), 
DlSCl; SSIOl\' 
The mouse ear mitosis assay provides a sensitive 
means of measuring the ability of agents to inhibit 
epidermal mitosis al the G2 stage of I he cell cycle. 
This is a locus for the regulation of cell division 
exerted by cyclic nucleotides: inhibitory a nd s lim -
ulatory effects a re observed for dibutyryl c~'clic 
AMP and dibutyryl cyclic GMP. respeclively. 
Since psoriasis has been related in some reports to 
a decrease in the levels of cyclic AMP [10 I and an 
increase in the le"els of cyclic GMP P31 in the 
epidermis. antimitotic activity observed in this in 
vitro assay may provide an indication of therapeu-
tic potential th rough a mechanism of action differ -
ent than those of currently a\'ailable products. 
The normally low mitotic rate of epidermal 
tissue has heretofore precluded its use in screening 
compounds for antimit.otic activity and has neces-
sitated use of more rapidly dividing tissue such as 
va~inal or rectal epithelium 114.15]. In the present 
TABLE JIJ. Effec:t of c:yclic nucleotides and related 
compound .... on mOuSe ear epiderm.al m itosis" 
Compound ConcentratIOn ';, Inh ibi tIon ( MI CJr miw!\ib~ 
Dibutyryl 5 ' to • 64 ~ 1:3 lp 0 .001) 
cAMP 
Monobu tyryl 5 JO • 38 to ( p 0 .008) 
cAMP 
Cyclic AMP 5 ' 10 • ~ 13lp - .95\ 
leA MP ) 
S' AMP 5 10 - ~ 24 9(p ~ .03) 
Sodium 10- • ~ 6 , 141p · .68) 
bUlyrate 
Theophylline ]0 4, ~ 8 ( p 0 .005) 
Papaverine 10 S , Sip < .OOt) 
Carbamyl 1 , 10 - 22 oC 34 ( p .561 
choline 1 , 10 • - 22 ~ 42 (p • . 63) 
1 , 10 - 67 ~ 92 (p - .48) 
" Experimental protocol as described for Table n. The 
numbers of mi toses in drug-treated ear plugs were 
compared with lhose in <.:ontrol plugs. ~egati\'e values 
indicate ~1 imulation of mitosis. Compa risons of means 
were made on the basis of Student's t-test and corre-
spond ing p values are given in parentheses. 
IJ Mean ± st.andard error. 
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TABLE IV . Effect of EGF pretreatmen.t on newborn rat 
and mouse epidermal mitoses" 
Mitoses per em epldermi!i 
Dose 
EGF Newborn ra t Newborn mouse 
I,gl 
E., Back Tail Ea, Back Tail 
0 19.8 6.5 8. 7 24.0 10.4 10.6 
1±2.3) (±I.4) 
20 34.3 9.7 52.5 14.4 54.6 
I ±o.n 1± 2.3 1 
50 46.8 18.8 22.0 
(± 3.3) 1± 5.8) 
100 57.0 33.4 38.3 
" Newborn rats or mice were t reated daily with EGF 
lsu bcu taneously) from birth for 7 to 8 days. Skin plugs 
from ears and back and segme nts from tails were exam-
ined for epidermal mit.oses. Values are averages from 1 LO 
6 animals a long with standard errors where appropriate. 
.\ 
\ 
/~ 
.. 
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fiG. 2. Effect of EGF on newborn ral ea r epidermal 
mitosis . Newborn rats were treated dailv fro m birth for 8 
to 9 days with EGF (20 J.l.g. 50 p , or foo J.l. g) or saline . 
subcutaneously . At various times during or following the 
t.reatment period. the rats were sacrificed a nd ear plugs 
were taken a nd examined for epidermal mit.oses as 
desc r ibed under Ma terials and Methods . 
studies it was found that reserpine pretreatment of 
mice. 24 hr prior to sacri fice . resulted in a repro-
ducible elevation in the number of mitotic cells in 
the in vit ro ea r assay. This dose- related elevation is 
presumed to result from a deplelion of ci rculating 
and/or skin catecholamines 116J, which are known 
to exert an inhibitory influen ce at the G 2 stage of 
the cell cycle 12,6,8, 17- 201. Restora tion of a basa l 
mitotic number by 48 hr is probably a reflection of 
partial repletion of catecholamines . Depression of 
mitosis by various agents can be more readily 
discerned, and with fewer experiments, with a 
basal index of 20- 25 versus 3- 4 mitoses per cm. 
Moreover, the innovation of reserpine pretreat-
ment to minimize an endogenous G 2 inhibitory 
influence was expected to increase the sensitivity 
to agents which act at G2 • This expectation was 
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realized with respect to isoproterenol, dibutyryl 
cyclic AMP. papaverine, and theophylline. lnvesti-
gations are in progress to elucidat.e reserpine-
induced effects on epidermal and dermal cyclic 
AMP and cyclic GMP levels and to determine 
whether its action on epidermal cell division may 
be related to the production of a psoriasiform 
condition in patients being treated with the beta 
adrenergic blocking agents, practolol and ox-
prenolol 121 - 241. 
Reserpine-enhanced mitodc activity is of addi ~ 
t ional interest in light of recent reports of increased 
incidence of breast cancer in hypertens ive patients 
receiving this drug 125- 27 J. The effect has been 
attributed t.o stimulation of the secret ion of proiae· 
tin, which is believed to be involved in mammary 
t.umor development in animals and possibly in 
humans [28). Chemical carci nogenicity via hy · 
droxyquinone generation in the cell has also been 
invoked as a poss ible mechanism 129- 31 J. The 
present data suggest the poss ibility that this side 
effect may involve decreased tissue c8techolamines 
and decreased levels of cvclic AMP and/or in-
creases in cyclic GMP. 
Pharmacologic characterization of the mouse ear 
mitos is assay was made with agents known to 
affeCl (',yelie nucleot ide levels. Isoproterenol at 10- 8 
M inhibited mitosis by 85 %. In ea r plugs from 
non -reserpine ~treaLed mice. considerably less inhi-
bition in this assay was achieved with JO- 8 M 
isoproterenol ~6 \. a concent.ralion at which we 
obtain nearly complete suppression of mit osis. 
Potentiation of responses of other tissues to iso· 
proterenol with reserpine has a lso been report ed 
T ABLE V. Effecl s of dibu tyryl cyclic AMP, isoproterenol. 
papa fJ erine and 8.brom o·cycli(' GMP on epiderm al 
mitoses of EGF- and saline-pretreated newborn ral s(l 
M iwse!' per em epiderm is~ 
C'Orfll)()und 
~ulin€, · ltea led EGF. lreated 
Dibutyryl 
cyclic AMP 2.7 :f. 1.4 7. 1 ± 3.0 
(5 x 1O ~ $ M) 1851 181 ) 
( - ) Isoprote renol 1.6 ~ 0.2 12.5 ± 1.8 
llO- l M) 191) (66) 
Papaverine 2.1 ± 0.7 4.3 .t. 1.1 
00- ' M ) 1881 (881 
B- Br·cyclic GM.P 10.9 ± 2.9 24.9 ± 2.9 
(5 )( 1O- ~ M) 133) (38) 
Contro l 17.5 01. 1.4 37.1 ±B.7 
(0) (0 ) 
" Newborn rats were treated d aily from bi.rth for 8 to 9 
days with EGF (50 j.lg/ rat/day ) or wil.h saline subcutane -
ously . Rats were sacr ificed and back skin was removed . 
Five 2.5 x 5 mm plugs were Laken from back skin and 
incubated with the indicated compounds fo r 5 hr . the last 
4 in the presence of demecolcine. Mitoses we re counted as 
described in Ma terials and M ethods. 
o Each value is t he mean ± st.andard error of mitoses 
from 3 fats . Numbers in parentheses indicate t he percent 
inhibi t. ion of control mitoses . 
May]976 
[32,33]. The effecliveness of propranolol and inef-
fectiveness of phentolamine in blocking the iso-
proterenol effect reflect an action mediated 
through p-adrenergic receptor activation , as previ-
ously reported [8 j. 
As anticipat,ed, both PGE, and PGE, were 
inhibitory to mitosis_ PGF,..., . which in several 
systems produces responses opposite to those of the 
PGEs [34- 36), also inhibited mitosis in dose-de-
pendent fashion from 10- ' to 10- ' M . Prostaglan-
din -induced accumulation of cyclic AMP has been 
reported in various tissues including epidermis 
[37-40,*), and it is likel y that this is the mecha-
n ism of prostaglandin inhibition of cell division in 
vilro [41- 44]. 
Dibutyryl cyclic AMP showed effective antimi -
totic activity with an le,o of 2 x lO- ~ M and 
com pletely inhibited mitosis at 5 x 10>' M . In 
similar systems using non -reserpine pretreated 
m ice, other workers have reported IC,o values of 5 
x 10- ' M cycl ic AMP in t he absence of theophyl -
line 19) and 5 x 10- ' M dibutyryl cyclic AMP in the 
presence of theophylline, 5 x 10- ' M 171, a Concen-
tration which itself produced nearly 20% inhibition 
of mitosis in those studies and over 50% inhibit.ion 
in OUt experiments . The discrepancy in effective-
ness of cyclic AMP in the above-mentioned study 
and our own remains to be explained. 
The inhibi tOry effect of 5' AMP is believed to 
occur through stimulation of adenylate cyclase. in 
a manner first reported for adenosine in brain 
slices [451. Adenosine and 5' AMP have been 
shown to stimulate mammalian epidermal slice 
cyclic AMP 1461 and epidermal cyclase 147 ) and. as 
in brain. the effects were inhibited by theophylline. 
In addition to exogenous dibutyryl cyclic AMP. 
papaverine and theophylline, which elevate intra-
cellular cyclic AMP levels by virt ue of inhibit ing 
its inactivation by phosphodiesterase, were po-
tently antimitotic at '10 >' M . Dibutyryl cyclic 
GMP, which is antagonistic to cyclic AMP in many 
proliferat ive processes. was inaet ive at lower con-
centrations. stimulaiory to mitosis at int.ermediate 
concentrat ions. and tended to be inhibit.ory at 
higher concentrations. High concentrations of cy-
clic GMP may act nonspecifically lO mimic cyclic 
AMP effects. Whether one obtains inhibition or 
stimulation with exogenous cvelie GMP may well 
depend on the basal tissue levels of this nucleotide . 
However . it should be noted that the use of 
reserpine probably does not optimize conditions for 
demonstrating mitot.ic stimulation. The cholin -
ergic stimulator, carbamyl choline, generally slim-
ulated mitosis (10 - ' 1010- ' M) but as with dibuty-
ryl cyclic GMP. this was highly variable from 
animal to animal. 
Experiments with EGF suggest that pretreat-
ment. of newborn mice or rats with this substance 
produces a condition of enhanced epidermal mi -
.. Aso K. Rabinowitz I. Oren berg E, Wilkinson D1. 
Farber EM : Impaired prostaglandin E release in hyper-
plast.ic epidermis of psoriasis; its implication for the 
pathophysiology of the disease (abstr) . lnternational 
Conference on Prostaglandins. Florence, May 26- 30.1975. 
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totic activity. Dibutyryl cyclic AMP and cyclic 
AMP elevators are effective in antagonizing this 
effect in vitro. EGF, a polypeptide isolated from 
male mouse submaxillary gland (11) , has been 
shown to stimulate epidermal growth in vivo Ill. 
see 48) to stimulate the proliferation of epithelial 
cells in culture Isee 48) and t.o decrease epidermal 
cyclic AMP levels and adenylate cyclase activity of 
newborn mice ,t The EGF-induced synthesis of 
RNA and DNA in human fibroblasts is inhibited 
by theophylline and/or dibutyryl cyclic AMP as 
well as by cholera toxin, whose actions are believed 
to be mediated through cyclic AMP 149]. While 
EGF has now been found in human serum 150 I and 
urine [51), it has not been implicated in psoriasis 
or other human proliferative dermatoses. However. 
EGF may represent a more ·'physiologic·· means of 
turning on cell division t han reserpine and its 
potential in screening for antimitotic compounds is 
being investigated further . 
Although a close relat ionship exists between 
cyclic AMP and mitosis. the mitotic assay may be 
superior to a cyclic AMP assay for screening G2 celJ 
cycle inhibitors acting t hrough a cyclic AMP 
mechanism. The mitotic assay is an integrator of 
possible multiple effects of compounds on both the 
cyclic AMP and cyclic GMP system whicb. on the 
basis of data presented here and el sewhere Isee 11, 
can act in opposing fashion to inhibit or to st imu-
late proliferation , respectively. Phosphodiesterase 
i.nh~bi.tot"s_ fCl t" example . can elevate both cyclic 
AMP and cyclic GMP by inhibition of the same or 
separate enzyme which have some selecti\' ity for 
each of t he two nucleotides [52,53 j. The net result. 
in terms of a cellular proliferative response. may 
depend more upon the relat.ive effect on t.he tWO 
nucleotides than upon either alone. 
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